Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A407S6 | ISIN: US60855D3098 | Ticker-Symbol: MOL
Lang & Schwarz
27.06.25 | 07:00
0,510 Euro
-100,00 % -0,510
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MOLECULIN BIOTECH INC Chart 1 Jahr
5-Tage-Chart
MOLECULIN BIOTECH INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,5000,52007:00

Aktuelle News zur MOLECULIN BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.06.Moleculin Biotech prices $5.9M public offering; shares down about 47%1
20.06.Moleculin Biotech preist öffentliches Angebot von 5,9 Millionen US-Dollar7
20.06.Moleculin Biotech prices $5.9 million public offering1
20.06.Moleculin Biotech, Inc.: Moleculin Announces $5.9 Million Public Offering1
18.06.Moleculin Gets Positive FDA Feedback On Pediatric Study Plan For Annamycin In Children With R/R AML3
18.06.Moleculin Biotech, Inc.: Moleculin Participates in Virtual Investor "What This Means" Segment3
18.06.FDA agrees to Moleculin's pediatric study plan for cancer drug8
18.06.Moleculin Biotech, Inc.: Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML663Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months - younger than...
► Artikel lesen
MOLECULIN BIOTECH Aktie jetzt für 0€ handeln
18.06.Moleculin Biotech, Inc. - 8-K, Current Report-
16.06.Moleculin Biotech, Inc. - S-1/A, General form for registration of securities2
11.06.Moleculin Biotech, Inc.: Moleculin Participates in Virtual Investor "What This Means" Segment1
06.06.Moleculin Biotech, Inc. - S-1/A, General form for registration of securities2
04.06.Moleculin Biotech, Inc.: Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)223Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement...
► Artikel lesen
04.06.Moleculin Biotech, Inc. - 8-K, Current Report2
02.06.Moleculin Biotech files to sell 10.99M shares of common stock, warrants1
02.06.Moleculin Biotech, Inc. - S-1, General form for registration of securities1
23.05.Moleculin Biotech, Inc. - 8-K, Current Report12
14.05.Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved8
14.05.Moleculin Biotech GAAP EPS of -$0.694
14.05.Moleculin Biotech, Inc.: Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update117Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML Regulatory and site selection progress to date supports...
► Artikel lesen
Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1